Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
The Chapter 11 bankruptcy filing of aaiPharma (Wilmington, NC, www.aaipharma.com), parent of AAI Development Services, was the culmination of an agonizing year-long odyssey. It also was a first step in restoring one of the best-known brands in the CRO industry.
Compounding Pharmacies' Lawsuit Against FDA Will Continue
The unit-dose bar coding rule requires integrating many aspects of packaging design and control.
Major pharmaceutical companies are focusing more than ever on the prices CROs are charging for their services.
Crucell and NIH Sign Ebola Vaccine Manufacturing Contract
Achieving the promised benefits of offshore sourcing to India and China is more complicated than it seems.
How important will anticounterfeiting measures become to protect the European pharma industry?
Today's fast-paced global market place has created a critical need for efficient international supply systems in the healthcare sector...
After a five-year downturn, cautious optimism is taking hold among API manufacturers.
Novartis to Expand Generics Hold
Too many players and threats to the main customer base challenge European dose manufacturers.
From solving complex formulation challenges to delivering full product-development programs, outsourcing services organizations provide valuable expertise, experience, and technical know-how.
Patheon is betting the whole is worth more than the sum of the parts in its acquisition of Puerto Rico contract manufacturer Mova.
The blockage in the new product pipeline may be breaking. CROs report increased demand for late-stage development services in their latest round of earnings reports.
What should pharmaceutical companies make of recent corporate developments at several high-profile service providers?
… the real glue that holds the partnership - and project - together, even more so than a formal contract or quality agreement, is the ability to communicate regularly and honestly with each other.
A big problem for the industry seems to be that Phase II has become something of a 'black hole' for drug development; new drug candidates can't seem to escape once they enter.
Beyond the inevitable debate over profit margins, the increasing range and effectiveness of modern medicine leave us with one core issue: the high price of success.
Big Pharma is ramping up capital spending in parenteral manufacturing at the same time that contract manufacturers are completing their own major investment programs.
Early development services continue to be a sweet spot for contract R&D services. The big question is how soon the impact of early-development candidates will be felt in late development and commercialization.
The contract services industry is fertile ground for the investment banking community this summer.
Data from the 2004 Outsourcing Survey indicate that pharmaceutical companies are spending more on outsourced drug development, but with fewer suppliers.
Corporate profile
Despite investors' strong interest in the chemical industry overall, pharmaceutical chemical businesses have not experienced much attention from investors thus far.
